Abbott Laboratories said it could resume infant formula production within two weeks at a Michigan manufacturing plant that has been shut since February because of bacterial contamination concerns, exacerbating a nationwide formula shortage.
The Illinois-based company said Wednesday it would resume production pending approval from the Food and Drug Administration, which has been conducting an investigation into whether bacterial contamination at the plant caused the illnesses of four babies, two of whom died, after being fed Abbott-brand formula. The babies were infected by a bacteria called cronobacter sakazakii, which is known to survive in dry foods such as infant formula powder.
To Read the Full Story
This post first appeared on wsj.com
